Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 65/100

Indivior Announces Q4 / FY 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023. The earnings release, investor...

Key Takeaway: Indivior PLC has announced its financial results for the fiscal year ending December 31, 2023. The company is dedicated to developing medicines for substance use disorders and serious mental illnesses. As a global pharmaceutical leader, Indivior aims to transform substance use disorders into recognized chronic diseases with adequate treatment options. The results are accompanied by a live webcast presentation featuring insights from CEO Mark Crossley.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior's financial results show promising growth and stability.
  • The company is focused on addressing significant global health issues related to substance use disorders.
  • Indivior has a diverse pipeline aimed at treating both opioid and alcohol use disorders.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV ) today announced its financial results for the period ending December 31, 2023 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am EST ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/kymnerij Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a
(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What financial results did Indivior announce?

Indivior announced its financial results for the year ending December 31, 2023.

How can I access the Indivior webcast?

You can access the Indivior webcast via the link provided in their announcement.

What is Indivior's main focus?

Indivior focuses on developing treatments for substance use disorders and serious mental illnesses.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, Virginia, USA.

In how many countries is Indivior's portfolio available?

Indivior's products are available in 37 countries worldwide.

Last updated: Feb 22, 2024